Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2017, 26(5):282-287

The mystery of HDL

Kaško M, Kaško V
Stryn Health Center, Sogn og Fjordane, Norway

Cardiovascular diseases are the leading cause of morbidity and mortality in the adult population. Atherosclerosis is widely considered to be the most important cause induced by risk factors, from which dyslipidemia is considered as the most complex factor. Coronary heart disease is the most widespread and most serious clinical manifestation of systemic atherosclerosis. The main pillar of the diagnostics and treatment of clinical manifestations of atherosclerosis is the examination of the lipid spectrum. In clinical practice, the effects of the HDL class are measured only by determining the concentration of HDL cholesterol. It is questionable whether this clinical approach provides sufficient information to evaluate both the overall cardiovascular risk and the effect of hypolipidemic therapy. The possibility to identify constellations / subpopulations of HDL could be beneficial in detecting a dysfunctional lipoprotein profile as a very early pathological condition of the cardiovascular system.

Keywords: HDL cholesterol; lipoprotein subfractions; atherosclerosis; coronary heart disease

Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kaško M, Kaško V. The mystery of HDL. Cardiology Letters. 2017;26(5):282-287.
Download citation

References

  1. Global Burden of Disease Study 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388: 1459-544.
  2. Zdravotnícka ročenka Slovenskej republiky 2015. Bratislava: Národné centrum zdravotníckych informácií; 2017.
  3. Gavornik P, Gaspar L, Dukat A, et al. Angiogénna koncepcia metabolického syndrómu. Viacnásobný cievny bludný kruh angiometabolického syndrómu. Ateroskleróza. 2012;16(12):230-237. Go to original source...
  4. Arsenault BJ, Lemieux I, Despres JP, et al. Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. Eur Heart J. 2007;28(22):2770-2777. Go to original source...
  5. Keene D, Price C, Shun-Shin MJ, et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;349:g4. Go to original source...
  6. Voight BF, Peloso GM, Orho-Melander M, et al. D. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-580. Go to original source...
  7. Nyyssönen K, Kurl S, Karppi J, et al. LDL oxidative modification and carotid atherosclerosis: results of a multicenter study. Atherosclerosis. 2012; 225(1):231-236. Go to original source...
  8. Weiner SD, Ahmed HN, Jin Z, et al. Systemic inflammation and brachial artery endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA). Heart. 2014;100(11):862-866. Go to original source...
  9. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Effects of obesity on lipidlowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol. 2006;97(11):1553-1537. Go to original source...
  10. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;1:CD003041. Go to original source...
  11. Oravec S, Dukat A, Gavornik P, et al. Contribution of the atherogenic lipoprotein profile to the development of arterial hypertension. Bratisl Lek Listy. 2011;112(1):4-7.
  12. Ounpuu S, Negassa A, Yusuf S. INTER-HEART: A global study of risk factors for acute myocardial infarction. Am Heart J. 2001;141(5):711-721. Go to original source...
  13. Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37(42):3232-3245. Go to original source...
  14. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation. 1992;85(1 Suppl):I2-10.
  15. Kostner GM, Laggner P. Chemical and physical properties of lipoproteins. In: Fruchart JC, Shepherd J, ed. Clinical Biochemistry - Human Plasma Lipoprotein. Berlin, New York: \X/ alter de Gruyter; 1989. Go to original source...
  16. De Lalla OF, Gofman JW. Ultracentrifugal analysis of serum lipoproteins. In: Glick D, ed. Methods of biochemical analysis. Vol 1. New York: Wiley; 1954. Go to original source...
  17. Siri-Tarino PW, Sun Q, Hu FB, et al. Saturated Fatty Acids and Risk of Coronary Heart Disease: Modulation by Replacement Nutrients. Curr Atheroscler Rep. 2010;12(6):384-390. Go to original source...
  18. Shin JY, Xun P, Nakamura Y, et al. Egg consumption in relation to risk of cardiovascular disease and diabetes: a systematic review and meta-analysis. Am J Clin Nutr. 2013;98(1):146-159. Go to original source...
  19. Gertler MM, Garn SM, White PD. Diet, serum cholesterol and coronary artery disease. Circulation. 1950;2(5). Go to original source...
  20. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84(4):1381-1478. Go to original source...
  21. Zerrad-Saadi A, Therond P, Chantepie, et al. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb Vasc Biol. 2009;29(12):2169-2175. Go to original source...
  22. Garner B, Waldeck AR, Witting PK, et al. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem. 1998;273(11):6088-6095. Go to original source...
  23. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58(3):342-374. Go to original source...
  24. Krychtiuk KA, Kastl SP, Pfaffenberger S, et al. Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. Atherosclerosis. 2014;237(2):589-596. Go to original source...
  25. Oravec S, Dukat A, Gavornik P, et al. Atherogenic versus nonatherogenic lipoprotein profiles in healthy individuals. Is there a need to change our approach to diagnosing dyslipidemia? Curr Med Chem. 2014;21(25):2892-2901. Go to original source...
  26. Ren J, Jin W, Chen H. oxHDL decreases the expression of CD36 on human macrophages through PPARgamma and p38 MAP kinase dependent mechanisms. Mol Cell Biochem. 2010;342(12):171-181. Go to original source...
  27. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; doi: 10.1056/NEJMoa1707914. [Epub ahead of print] Go to original source...
  28. Dukat A, Simko F. Circulating microparticles - new risk factor, or biomarker for cardiovascular diseases? Cardiology Lett. 2016;25(2):85-90.
  29. Aboyans V, Mcclelland RL, Allison MA, et al. Prevalence and risk factors of lower extremity artery disease in subjects without traditional modifiable cardiovascular risk factors. The multi-ethnic study of atherosclerosis. Arch Cardiovasc Dis Supplements. 2011;3:72-78. Go to original source...
  30. Haase CL, Tybjaerg-Hansen A, Grande P, et al. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Clin Endocrinol Metab. 2010;95(12):E500-10. Go to original source...